Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,266

By adulthood, the heart is no longer able to replenish injured or diseased cells. As a result, heart disease or an event like a heart attack can be disastrous, leading to massive cell death and permanent declines in function. A new study by scientists at the Lewis Katz School of Medicine at Temple University (LKSOM), however, shows that it may be possible to reverse this damage and restore heart function, even after a severe heart attack.

The study, published June 21 in the print edition of the journal Circulation Research, is the first to show that a very small RNA molecule known as miR-294, when introduced into , can reactivate cell proliferation and improve heart function in mice that have suffered the equivalent of a in humans.

“In previous work, we discovered that miR-294 actively regulates the in the developing heart,” said Mohsin Khan, Ph.D., Assistant Professor of Physiology at the Center for Metabolic Disease Research at LKSOM. “But shortly after birth miR-294 is no longer expressed.”

Read more | >

Gensight Biologics, a company researching – among other things – the movement of mitochondrial genetic information to the nucleus to treat hereditary genetic diseases (a strategy that could also have an impact on aging according to the SENS Research Foundation), has recently released data for its latest trial of GS010, a therapy against the blindness-causing genetic disease LHON.

Note: Patrick Deane holds shares in Gensight Biologics (EPA: SIGHT).

Read more | >

Genes get shuffled and re-dealt with every new generation, meaning many are relatively recent. But while exploring the “dark heart” of the human genome, geneticists have now found some of the most ancient pieces of DNA, inherited from Neanderthals and an as-yet-unknown human relative, which may be affecting our sense of smell to this day.

Read more | >

Over 30 years ago, a molecule with incredible anti-cancer properties was discovered in sea sponges. However, it was so structurally complex scientists have been unable to synthesize it in large enough quantities to be able to test it in humans. Now a team of scientists has finally made a landmark breakthrough, achieving total synthesis of the molecule in volumes large enough to proceed to clinical trials.

Read more | >

Though serotonin is well known as a brain neurotransmitter, it is estimated that 90 percent of the body’s serotonin is made in the digestive tract. In fact, altered levels of this peripheral serotonin have been linked to diseases such as irritable bowel syndrome, cardiovascular disease, and osteoporosis. New research at Caltech, published in the April 9 issue of the journal Cell, shows that certain bacteria in the gut are important for the production of peripheral serotonin.

Read more | >